Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of nucleic acid lateral flow immunoassay (NALFIA). These antibodies can specifically bind to small molecule labels and offer customers multiple choices, including Anti Digoxin monoclonal antibodies, Anti-Fluorescien monoclonal antibodies, and Anti-FAM polyclonal antibodies.
Traditional nucleic acid detection methods require trained operators and sophisticated instrumentation, with signal reading and detection times often taking hours. With the increasing demand for diagnostics in resource-limited settings, lateral flow assays (LFAs) for nucleic acid testing are receiving increasing attention due to their low cost and ease of use. They have also shown great potential in point-of-care testing (POCT).
Currently, target gene amplification has been widely used in diagnostic settings. Among them, polymerase chain reaction (PCR) and isothermal methods such as loop-mediated isothermal amplification (LAMP), multiple cross displacement amplification (MCDA), and recombinase polymerase amplification (RPA) have been introduced into the lateral flow immunoassay (LFIA) of nucleic acids, termed nucleic acid lateral flow immunoassay (NALFIA). NALFIA combines lateral flow technology with immunoassay principles for the detection of nucleic acid-related products.
A typical workflow for nuclear lateral flow testing includes nucleic acid extraction from biological samples, nucleic acid amplification, and detection of amplicons by LFAs using colorimetric labeling materials. For NALFIA, both forward and reverse primers are typically labeled with biotin and another antigen with high antibody affinity (e.g., digoxin (DIG), carboxyfluorescein (FAM), and/or FITC). In this way, the amplicon is doubly labeled and forms a sandwich-type complex through a high-affinity immunoreaction between the antigen and the antibody. Each monoclonal antibody specifically recognizes the corresponding tag.
For example, the Anti Digoxin monoclonal antibody (Catalog # CABT-L2334) is suitable for use in ELISA. Digoxin is a beta-blocker drug originally derived from the foxglove plant, Digitalis lanata. Digoxin is used primarily to improve the heart’s ability to pump blood in patients with congestive heart failure (CHF) and to treat problems such as high blood pressure. It is also used to help normalize certain heart arrhythmias (abnormal types of heartbeats).
Another is the Anti-Fluorescien monoclonal antibody (Catalog # DMAB7251). FITC (fluorescein isothiocyanate) is a fluorescent dye that absorbs ultraviolet or blue light, causing the molecule to excite and emit visible yellow-green light. This emission stops when the light that caused the excitation is removed. When one of the reactants is part of a cell, tissue, or other biological structure, fluorescent labeling can quickly and accurately localize antigen-antibody interactions. FITC is a commonly used antibody marker in immunofluorescence techniques because it is relatively easy to attach to proteins and generally does not interfere with the biological activity of the labeled proteins. FITC is used to label a wide range of different proteins.
To learn more information about the Anti-Small Molecule Label Antibodies, please visit https://www.creative-diagnostics.com/tools-for-nucleic-acid-lateral-flow-immunoassay-nalfia-anti-small-molecule-label-antibodies.htm.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.
Be the first person to like this.
As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has recently announced the launch of its new Checkerboard Assay services to support researchers in evaluating the interaction of two antimicrobial test compounds, including Standard Bacteria Culturing, Antimicrobial Synergy Testing, and Statistics Analysis of experimental results.
The checkerboard test is an experimental method used to evaluate the interaction of two antimicrobial test compounds. In this test, the MIC and MBC values of the test compounds are used individually and combined with the MIC and MBC values of each bacterial strain being evaluated to calculate accumulation.
Synergy measurements by checkerboard analysis can be utilized to determine changes in the antibacterial potency of an antibiotic combination relative to its activity. Comparative results are then calculated using the Fractional Inhibitory Concentration (FIC) index value, which shows the greatest change in antibiotic combinations compared to the MIC of a single antibiotic.
Creative Diagnostics now offers a series of Checkerboard Assay services to the research communities, including Standard Bacteria Culturing, Antimicrobial Synergy Testing, and Statistics Analysis of experimental results. Creative Diagnostics works with scientists in industry and academia to support the early stages of antimicrobial, vaccine and diagnostic discovery and to advance research in bacterial infections.
Before testing, a stock solution and two serial dilutions of at least twice the MIC should be prepared for each drug. A total of 50 μL of Müller-Hinton broth is then injected into each well of the microdilution plate. Next, the first antibiotic in the combination is sequentially diluted along the ordinate and the second drug is diluted along the abscissa. An inoculum equivalent to 0.5 McFarland turbidity standard is then prepared from each isolated Pseudomonas aeruginosa and placed in Müller-Hinton broth.
Finally, 100 μl of 5 x 105 CFU/ml bacterial inoculum is inoculated into each microwell and incubated for 48 hours at 35°C under aerobic conditions. The resulting checkerboard grid contains each combination of the two antibiotics, with the diagonal representing the tube with the highest concentration of each antibiotic. To quantify the interaction between the tested antibiotics (the FIC index), researchers can calculate using the following formula: A /MIC A + B/MIC B = FIC A + FIC B= FIC Index. When the FIC value is <0.5, the two antibiotics are synergistic; when the FIC is >4, the two antibiotics are antagonistic; and when the FIC is 0.5-4, the two are either additive or non-additive.
Creative Diagnostics offers assays for the major bacterial families and can help customers select the appropriate assay based on the compound and mechanism of action. The company can also develop custom assays based on customers’ specific processes. For more information, please visit https://antiviral.creative-diagnostics.com/antimicrobial-synergy-testing-checkerboard-assay.html.
About Creative Diagnostics
Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, and biosafety regulation elucidation, to expert viral system assistance.
Be the first person to like this.
Creative Diagnostics, a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for food, feed, environmental and toxicological sample analysis, has announced the release of its new line of Azaperone Test Reagents, including Azaperone ELISA Kits, Azaperone Residue Rapid Test Strips, and Azaperone Antibodies & Antigens. These reagents are designed to assist researchers in the detection of Azaperone.
Azaperone is an important butylphenol benzene neurostabilizer used in veterinary practice. It has a variety of neurostabilizing effects associated with farm animals. Intramuscular injections of this drug are used to relieve tension and reduce activity in animals. It causes animals to be indifferent to their environment and remain calm for long periods, which helps to avoid fighting when they live together and mix in herds. For this reason, it is often used for long-distance transportation of animals such as pigs. With the widespread use of this drug in the veterinary field, the problem of its residues in animal tissues and the direct danger of its toxic side effects on human health have attracted widespread attention.
Creative Diagnostics is committed to developing quality detection reagents to support the development of sedative testing. Through years of research and experience of its technical staff, the company has successfully developed a range of antigens and antibodies for immunoassays and established enzyme-linked immunosorbent assay (ELISA) and lateral flow immunoassay (LFIA) detection platforms.
Creative Diagnostics now offers a series of Azaperone Test Reagents for research applications, including Azaperone Antibodies & Antigens, Azaperone ELISA Kits, and Azaperone Screen Tests. For example, the new Azaperone [OVA] (#DAGA-227O) and Mouse Anti-Azaperone Monoclonal Antibody (#CABT-L3081) can be used to detect Azaperone residues by ELISA and IFIA. These antigens and antibodies have been extensively validated and characterized. Meanwhile, the antigens are analyzed by UV-visible spectroscopy and sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Antibody sensitivity is determined by icELISA to determine the 50% inhibitory concentration (IC50), and antibody specificity is determined by measuring cross-reactivity (CR) with other structural analogs.
Creative Diagnostics also offers icELISA for the detection of Azaperone residues in pork and pork liver. The linear range of the kit has been tested to be 0.165-1.29 ng/mL with a sensitivity of 0.5 ng/mL or greater. The CV is less than 15%. In addition, Creative Diagnostics provides Lateral Flow ICA Test Strip, a faster and easier diagnostic tool for on-site testing. The visual limit of detection and critical value for azaperone in Lateral Flow ICA are 0.5 and 10 ng/g, respectively. Both methods are sensitive, fast, and effective for on-site testing and rapid bulk screening of samples.
For more information about these new Azaperone Test Reagents, please visit https://www.creative-diagnostics.com/food-analysis/azaperone.html.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, small molecule conjugates and critical assay reagents for the analysis of food, feed, environmental and toxicological samples. Its product portfolio covers a wide range of analytes including mycotoxins, drug residues, pesticides, contaminants, food allergens, food pathogens and vitamins. The company also assists customers in the rapid development, manufacture and commercialization of small molecule antigens, antibodies and food safety lateral flow strips for any market segment.
Be the first person to like this.